These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 20421548)
1. Public disclosure of conflicts of interest: moving the policy debate forward. Campbell EG Arch Intern Med; 2010 Apr; 170(8):667. PubMed ID: 20421548 [No Abstract] [Full Text] [Related]
2. Doctors and the drug industry: reader feedback. Nardone DA Am J Med; 2005 Oct; 118(10):1176-7; author reply 1177. PubMed ID: 16194658 [No Abstract] [Full Text] [Related]
3. The devil in the detail(ing). Morreim H Am J Bioeth; 2010 Jan; 10(1):15-7. PubMed ID: 20077328 [No Abstract] [Full Text] [Related]
4. The details are in the field. Schwab AP Am J Bioeth; 2010 Jan; 10(1):19-21. PubMed ID: 20077330 [No Abstract] [Full Text] [Related]
5. Huddle gets it right, most docs don't. Rubin PH Am J Bioeth; 2010 Jan; 10(1):17-9. PubMed ID: 20077329 [No Abstract] [Full Text] [Related]
6. Why academic medical centers should ban drug company gifts to individuals. Strong C Am J Bioeth; 2010 Jan; 10(1):13-5. PubMed ID: 20077327 [No Abstract] [Full Text] [Related]
7. Drug detailers, professionalism, and prudence. Brody H Am J Bioeth; 2010 Jan; 10(1):9-10. PubMed ID: 20077325 [No Abstract] [Full Text] [Related]
8. Avoiding over-deterrence in managing physicians' relationships with industry. Stell LK Am J Bioeth; 2010 Jan; 10(1):27-9. PubMed ID: 20077334 [No Abstract] [Full Text] [Related]
9. Response to open peer commentaries on "The pitfalls of deducing ethics from economics: why the Association of American Medical Colleges is wrong about pharmaceutical detailing". Huddle TS Am J Bioeth; 2010 Jan; 10(1):W1-3. PubMed ID: 20077322 [No Abstract] [Full Text] [Related]
10. Contact with pharmaceutical representatives: where does prudence lead? Appelbaum PS Am J Bioeth; 2010 Jan; 10(1):11-3. PubMed ID: 20077326 [No Abstract] [Full Text] [Related]
11. Financial disclosures in clinical practice guidelines. Kahn JM; Rubenfeld GD Crit Care Med; 2010 Aug; 38(8):1755-6; discussion 1756-7. PubMed ID: 20647810 [No Abstract] [Full Text] [Related]
12. The AAMC exhibits the behavior it condemns. Stossel TP Am J Bioeth; 2010 Jan; 10(1):26-7. PubMed ID: 20077333 [No Abstract] [Full Text] [Related]
13. The pitfalls of misreading: what does "industry funding of medical education" actually say? Spielman B Am J Bioeth; 2010 Jan; 10(1):24-5. PubMed ID: 20077332 [No Abstract] [Full Text] [Related]
15. Doctors and the drug industry: further thoughts for dealing with potential conflicts of interest? Alpert JS Am J Med; 2008 Apr; 121(4):253-5. PubMed ID: 18374678 [No Abstract] [Full Text] [Related]
16. Doctors and the drug industry: reader feedback. Warrier R; Houghton B Am J Med; 2005 Oct; 118(10):1175-6; author reply 1176. PubMed ID: 16194656 [No Abstract] [Full Text] [Related]
17. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement. Moynihan R BMJ; 2003 May; 326(7400):1189-92. PubMed ID: 12775621 [TBL] [Abstract][Full Text] [Related]
18. Medicine and the pharmaceutical industry: a call to action. Stiles MM; Barrett B Am Fam Physician; 2007 May; 75(10):1447, 1451; discussion 1451. PubMed ID: 17555137 [No Abstract] [Full Text] [Related]
19. Physician investment in the health care industry: a concern. Watts C Surg Neurol; 2009 Oct; 72(4):401-2. PubMed ID: 18786706 [No Abstract] [Full Text] [Related]